Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells

Synapse

Volumn 47, Issue 4, 2003, Pages 285-294

  Ninan, Ipe ^a   Jardemark, Kent E ^a   Liang, Xiaofu ^a   Wang, Rex Y ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Antipsychotic drugs; CaMKII; Clozapine; Electrophysiological recording; Medial prefrontal cortex; NMDA receptors

Indexed keywords

2 [N (4 METHOXYBENZENESULFONYL)]AMINO N (4 CHLOROCINNAMYL) N METHYLBENZYLAMINE PHOSPHATE; CLOZAPINE; KN 92; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE (CALCIUM,CALMODULIN) II; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; EXCITATORY POSTSYNAPTIC POTENTIAL; FACILITATION; INTRACELLULAR RECORDING; NEUROTRANSMISSION; NONHUMAN; PATCH CLAMP; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SCHIZOPHRENIA; VOLTAGE CLAMP;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZYLAMINES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CLOZAPINE; ELECTRIC STIMULATION; ENZYME INHIBITORS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; MICE; MUTATION; N-METHYLASPARTATE; ORGAN CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; SULFONAMIDES;

EID: 0037445064     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10175     Document Type: Article

References (65)

1. Abraham WC, Tate WP. 1997. Metaplasticity: a new vista across the field of synaptic plasticity. Prog Neurobiol 52:303-323.
2. Arvanov VL, Wang RY. 1997. NMDA-induced response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Res 768:361-364.
3. 2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209.
4. Arvanov VL, Wang RY. 1999. Clozapine, but not haloperidol, prevents the functional hyperactivity of NMDA receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289:1000-1006.
5. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. 1997. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234.
6. 2A receptor agonist DOB on NMDA-evoked responses in pyramidal neurons of the rat medial prefrontal cortex. Eur J Neurosci 11:2917-2934.
7. Arvanov VL, Liang X, Russo A, Wang RY. 1999b. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J Neurosci 11:3064-3072.
8. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. 2001. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature 411:801-805.
9. Beasley Jr CM, Tollefson GD, Tran PV. 1997. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 10:7-12.
10. Blitzer RD, Wong T, Nouranifar R, Iyengar R, Landau EM. 1995. Postsynaptic cAMP pathway gates early LTP in hippocampal CA1 region. Neuron 15:1403-1414.
11. Blitzer RD, Connor JH, Brown GP, Wong T, Shenolikar S, Iyengar R, Landau EM. 1998. Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP. Science 280:1940-1942.
12. Carlsson M, Carlsson A. 1990. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 16:425-432.
13. Cauli B, Audinat E, Lambolez B, Angulo MC, Ropert N, Tsuzuki K, Hestrin S, Rossier J. 1997. Molecular and physiological diversity of cortical nonpyramidal cells. J Neurosci 17:3894-3906.
14. Chakravarthy B, Morley P, Whitfield J. 1999. Ca2+-calmodulin and protein kinase Cs: a hypothetical synthesis of their conflicting convergences on shared substrate domains. Trends Neurosci 22:12-16.
15. 1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324-2336.
16. Colbran RJ, Soderling TR. 1990. Calcium/calmodulin-independent autophosphorylation sites of calcium/calmodulin-dependent protein kinase II. Studies on the effect of phosphorylation of threonin 305/ 306 and serine 314 on calmodulin binding using synthetic peptides. J Biol Chem 265:11213-11219.
17. Connors BW, Gutnick MJ. 1990. Intrinsic firing patterns of diverse neocortical neurons. Trends Neurosci 13:99-104.
18. Daly DA, Moghaddam B. 1993. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152:61-64.
19. Derkach V, Barria A, Soderling TR. 1999. Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA 96:3269-3274.
20. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. 1989. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12:1-13.
21. Fan GH, Wang LZ, Qiu HC, Ma L, Pei G. 1999. Inhibition of calcium/ calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence. Mol Pharmacol 56:39-45.
22. Frankland PW, O'Brien C, Ohno M, Kirkwood A, Silva AJ. 2001. Alpha-CaMKII-dependent plasticity in the cortex is required for permanent memory. Nature 411:309-313.
23. Gerendasy DD, Sutcliffe JG. 1997. RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol 15:131-163.
24. Giese KP, Fedorov NB, Filipkowski RK, Silva AJ. 1998. Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science 279:870-873.
25. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. 1993. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702-712.
26. Halliwell JV, Adams PR. 1982. Voltage-clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res 250:71-92.
27. Hanson PI, Schulman H. 1992. Inhibitory autophosphorylation of multifunctional Ca2+/calmodulin-dependent protein kinase analyzed by site-directed mutagenesis. J Biol Chem 267:17216-17224.
28. Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R. 2000. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287:2262-2267.
29. Holmes K, Keele B, Arvanov V, Shinnick-Gallagher P. 1996. Metabotropic glutamate receptor agonist-induced hyperpolarization in rat basolateral amygdala neurons: receptor characterization, second messengers and ion channels. J Neurophysiol 76:3059-3069.
30. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
31. Itoh H, Hidaka H. 1984. Direct interaction of calmodulin antagonists with Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase. J Biochem (Tokyo) 96:1721-1726.
32. Jardemark KE, Ai J, Liang X, Wang RY. 2000. The role of calcium/calmodulin dependent kinase II in clozapine's facilitation of NMDA-induced currents in frontal cortical cells. Soc Neurosci Abstr 26: 2328.
33. Jardemark KE, Ai J, Ninan I, Wang RY. 2001. Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. Synapse 41:294-300.
34. Jardemark KE, Ninan I, Liang X, Wang RY. 2003. Protein kinase c is involved in clozapine's facilitation of N-methyl-d-aspartate- and electrically-evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience (In press).
35. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
36. Kawaguchi Y, Kubota Y. 1996. Physiological and morphological identification of somatostatin- or vasoactive intestinal polypeptide-containing cells among GABAergic cell subtypes in rat frontal cortex. J Neurosci 16:2701-2715.
37. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
38. Kennedy MB. 2000. Signal-processing machines at the postsynaptic density. Science 290:750-754.
39. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. 1980. Low cerebrospinal fluid gluatamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci Lett 20:379-382.
40. Liang X, Jardemark KE, Wang RY. 1999. Facilitation of the N-methyl-D-aspartate responses in pyramidal cells of the medial prefrontal cortex by clozapine: role of protein kinase C. Soc Neurosci Abstr 25:2048.
41. Lidsky TI, Yablonsky-Alter E, Zuck L, Banerjee SP. 1993. Antiglutamatergic effects of clozapine. Neurosci Lett 163:155-158.
42. Lisman JE, Goldring MA. 1988. Feasibility of long-term storage of graded information by the Ca2+/calmodulin-dependent protein kinase molecules of the postsynaptic density. Proc Natl Acad Sci USA 85:5320-5324.
43. Lisman J, Malenka RC, Nicoll RA, Malinow R. 1997. Learning mechanisms: the case for CaMKII. Science 276:2001-2002.
44. Lynch DR, Gallagher MJ. 1996. Inhibition of N-methyl-D-aspartate receptors by haloperidol; developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther 279:154-161.
45. McCormick DA, Connors BW, Lighthall JW, Prince DA. 1985. Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. J Neurophysiol 54:782-806.
46. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436.
47. Ninan I, Jardemark K, Wang RY. 2001. Diffrential effects of atypical and typical antipsychotic drugs on NMDA receptor mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex. Soc Neurosci Abstr 27:664-10.
48. Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
49. 2+/calmodulin-dependent protein kinase II. 22:4406-4411.
50. Rainnie DG, Holmes KH, Shinnick-Gallagher P. 1994. Activation of postsynaptic metabotropic glutamate receptors by trans-ACPD hyperpolarizes neurons of the basolateral amygdala. J Neurosci 14: 7208-7220.
51. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237.
52. Rongo C, Kaplan JM. 1999. CaMKII regulates the density of central glutamatergic synapses in vivo. Nature 402:195-199.
53. Shen K, Meyer T. 1999. Dynamic control of CaMKII translocation and localization in hippocampal neurons by NMDA receptor stimulation. Science 284:162-166.
54. Shen K, Teruel MN, Connor JH, Shenolikar S, Meyer T. 2000. Molecular memory by reversible translocation of calcium/calmodulin-dependent protein kinase II. Nat Neurosci 3:881-886.
55. Soderling TR, Chang B, Brickey D. 2001. Cellular signaling through multifunctional Ca2+/calmodulin-dependent protein kinase II. J Biol Chem 276:3719-3722.
56. Strack S, Barban MA, Wadzinski BE, Colbran RJ. 1997. Differential inactivation of postsynaptic density-associated and soluble Ca2+/ calmodulin-dependent protein kinase II by protein phosphatases 1 and 2A. J Neurochem 68:2119-2128.
57. Tanaka E, North AR. 1993. Action of 5-hydroxytryptamine on neurons of rat cingulate cortex. J Neurophysiol 89:1749-1757.
58. Tarazi FI, Floriji J, Creese I. 1996. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 128:371-379.
59. Tollefson GD, Sanger TM. 1997. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466-474.
60. 2A receptor antagonist and a potential antipsychotic drug, facilitates induction of long-term potentiation in area CA1 of the rat hippocampal slice. Brain Res 779:309-313.
61. Wang RY, Liang X. 1998. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19:74-85.
62. Wang RY, Liang X, Jardemark KE, Arvanov V. 2000. Facilitation of NMDA transmission by olanzapine. In: Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G, editors. Olanzapine (Zyprexa) - a novel antipsychotic. Baltimore: Williams & Wilkins. p 114-131.
63. Wuarin JP, Peacock WJ, Dubeck FE. 1992. Single-electrode voltage clamp analysis of the N-methyl-D-aspartate component of synaptic responses in neocortical slices from children with intractable epilepsy. J Neurophysiol 67:84-93.
64. Yamamoto BK, Pehek EA, Meltzer HY. 1994. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55:8-14.
65. Yang CR, Seamans JK, Gorelova N. 1996. Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. J Neurosci 16:1904-1921.